Lupin Limited has informed the Exchange regarding a press release dated August 11, 2025, titled "Lupin Launches Glucagon for Injection USP, 1mg/Vial in the United States".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has launched Glucagon for Injection USP, 1mg/vial (packaged in an emergency kit) in the US market. The product is bioequivalent to Eli Lilly's Glucagon for Injection and is used to treat severe hypoglycemia in diabetes patients and as a diagnostic aid. The addressable US market for this product is estimated at USD 122 million annually, based on IQVIA MAT June 2025 data. This adds to Lupin's growing portfolio of complex generics in the US, its largest market outside India.
This launch gives Lupin access to a USD 122 million US market opportunity, which could boost US revenues and support growth in its complex generics segment. Positive for the stock, though the actual revenue contribution will depend on market share Lupin is able to capture against existing players.